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Summary
Pathological expression of human ErbB-2 protein, also known as HER-2, is common in many types of cancer. ErbB-2 is
a member of the EGF receptor tyrosine kinase family and has been rigorously studied as a signaling molecule on the cell
membrane. Here, we report that ErbB-2 is also expressed in the nucleus in cultured cells as well as primary tumor tissues.
Nuclear ErbB-2 was found to associate with multiple genomic targets in vivo, including the cyclooxygenase enzyme COX-2
gene promoter. ErbB-2 forms a complex at a specific nucleotide sequence of the COX-2 promoter and is able to stimulate
its transcription. This study demonstrates the presence of ErbB-2 in the nucleus and identifies the function of ErbB-2 as
a transcriptional regulator.
Introduction functions, ranging from proliferation, differentiation, survival,
and motility to adhesion. In breast cancer, ErbB-2 overexpres-
sion can be observed in 15%–30% of invasive ductal carcinoma.The proto-oncogene ErbB-2 encodes a 185 kDa tyrosine kinase
receptor that belongs to the epithelial growth factor receptor Elevated ErbB-2 expression is associated with promoted prolif-
eration potential, enhanced resistance to apoptotic stimuli, and(EGFR) family (Yarden and Sliwkowski, 2001). There are four
members in the EGFR family, namely ErbB-1 (EGFR), ErbB-2 lymph node metastasis (Holbro et al., 2003). Due to its important
role in tumor development, targeting ErbB-2 has become a(HER-2/neu), ErbB-3, and ErbB-4. Each of these four receptors
contains an extracellular domain, a hydrophobic transmembrane critical area for breast cancer therapy (Arteaga, 2003; Yarden
and Sliwkowski, 2001; Mendelsohn and Baselga, 2000).domain, and an intracellular domain. Except for ErbB-3, the
intracellular domains of the EGFR proteins contain intrinsic tyro- The cyclooxygenase enzyme COX-2 catalyzes the conver-
sion of lipids to inflammatory prostaglandins. It is well docu-sine kinase activity. Upon stimulation, these receptors form
homodimers or heterodimers with other EGFR members and mented that COX-2 expression contributes to increased anti-
apoptotic, proangiogenic, and metastatic potential in cancerbecome activated through tyrosine phosphorylation. Although
no known ligand binds to ErbB-2 with high affinity, ErbB-2 itself cells and COX-2 deregulation is correlated with tumor progres-
sion (Rajnish et al., 2001; Turini and DuBois, 2002). Transcrip-is a preferred coreceptor for other members of the EGFR family
to form high-affinity complexes for different ligands (Graus- tional upregulation of the COX-2 gene by ErbB-2 expression
has been found in cultured cancer cells (Half et al., 2002; HowePorta et al., 1997). The activated receptor complexes conse-
quently recruit other signaling molecules and activate numerous et al., 2001; Subbaramaiah et al., 2002; Vadlamudi et al., 1999)
and in a c-erbB-2 transgenic animal model (Kiguchi et al., 2001).downstream signaling cascades, such as the mitogen-activated
protein kinases (MAPKs) and the phosphatidylinositol 3-OH ki- Consistently, significant correlation of COX-2 and ErbB-2 ex-
pression has been reported in several human cancer types,nase (PI3K) pathways. Through these signaling cascades,
ErbB-2 and its family members regulate a variety of cellular including cholangiocarcinoma, colon cancer, and breast cancer
S I G N I F I C A N C E
Many membrane receptor tyrosine kinases (RTKs), including the EGF receptor proteins, VEGF receptor, FGF receptor, insulin receptor,
and NGF receptor, have recently been found in the nucleus. However, the nuclear functions of these RTKs are largely unknown due
to the lack of knowledge on their nuclear targets. In the current study, we demonstrate that human ErbB-2, the clinically important
RTK associated with multiple types of human cancer, is also located in the nucleus, and we identify multiple genomic targets of the
nuclear ErbB-2, including the cyclooxygenase enzyme COX-2 promoter. The same experimental strategy, which combines molecular
and bioinformatic approaches, could be applied to other membrane RTKs expressed in the nucleus and may open a novel avenue
to understanding their nuclear functions.
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(Endo et al., 2002; Howe et al., 2001; Vadlamudi et al., 1999). pressed a basal level of ErbB-2 (data not shown). Consistent
with these results, ErbB-2 protein was detected in the nuclearIndeed, a recent large-scale clinical investigation involving 1576
patients with breast cancer revealed a significant correlation fraction of ErbB-2-expressing breast cancer cells by cellular
fractionation and immunoblot analysis (Figure 1H). It is knownbetween COX-2 and ErbB-2 expression in primary tumors (Risti-
ma¨ki et al., 2002). that tyrosine kinase activity of tyrosine kinase receptors is re-
quired for endocytosis, so we also examined nuclear expressionAlthough it is commonly accepted that tyrosine kinase re-
ceptors such as the EGFR family proteins function as signaling of ErbB-2 in the presence of a ErbB-2-specific kinase inhibitor
AG825 (Levitzki and Gazit, 1995). The result indicated that theinitiators on the cell membrane, there is accumulating evidence
indicating nuclear expression of growth factors and their recep- kinase inhibitor blocked nuclear expression of ErbB-2, sug-
gesting that tyrosine kinase activity is required for nuclear trans-tors (Carpenter, 2003; Clevenger, 2003; Keresztes and Boons-
tra, 1999; Wells and Marti, 2002). In addition to the EGFR family location of ErbB-2 (Figure 1I). In addition to cell lines, we also
detected nuclear ErbB-2 in multiple types of primary humanproteins ErbB-1, ErbB-3, and ErbB-4 (Lin et al., 2001; Ni et al.,
2001; Offterdinger et al., 2002; Xie and Hung, 1994), nuclear tumor tissue by immunohistochemical staining (Figure 6). Thus,
the ErbB-2 thought to be a cell surface membrane receptortranslocation of other tyrosine kinase receptors, including vas-
cular endothelial growth factor (VEGF) receptor (Feng et al., can be detected in the nucleus by four different approaches,
including fluorescence microscopy, electron microscopy, bio-1999), nerve growth factor (NGF) receptor (Rakowicz-Szulczyn-
ska et al., 1988), and fibroblast growth factor (FGF) receptor chemical fractionation, and immunohistochemistry in tumor tis-
sues (Figure 6). These results also suggest that nuclear ErbB-2(Maher, 1996; Reilly and Maher, 2001), have been reported.
However, the potential nuclear functions of these receptors/ is an intact molecule, as it can be detected by antibodies against
both N- and C-terminal epitopes of ErbB-2 protein and the sizeligands remain elusive due to the fact that a systemic approach
to identify their nuclear targets has not been established. To of nuclear ErbB-2 is the same as that of cytoplasmic ErbB-2.
this regard, it is known that the carboxy-terminal acidic regions
of EGFR and ErbB-4 contain an intrinsic transactivation function Binding of nuclear ErbB-2 to a specific DNA
sequence of the COX-2 promoterand are able to transactivate a luciferase-based report system
(Lin et al., 2001; Ni et al., 2001). Indeed, we previously demon- To elucidate the function of nuclear ErbB-2, we explored the
potential role of ErbB-2 as a gene regulator by investigatingstrated that the nuclear EGFR functions as a transcription factor
to stimulate cyclin D1 expression (Lin et al., 2001). Like EGFR the genomic targets associated with ErbB-2 using chromatin
immunoprecipitation (ChIP). DNA fragments associated withand ErbB-4, the carboxyl terminus of ErbB-2 is also highly
acidic, and this feature is conserved across different species, ErbB-2 were processed, cloned, and identified by sequencing,
as depicted in Figure 2A. The promoter regions or introns identi-including human, mouse, and rat (Xie and Hung, 1994).
In the current study, we provide evidence for nuclear expres- fied by these clones were further verified by ChIP. Using this
protocol, the genomic sequences of PRPK (Abe et al., 2001),sion and function for human ErbB-2 protein and identify important
genomic targets of ErbB-2 using a strategy combining chroma- MMP-16 (Will and Hinzmann, 1995), DDX-10 (Savitsky et al.,
1996), and COX-2 (Jones et al., 1993) associated with ErbB-2tin immunoprecipitation, molecular cloning, and bioinformatic
analysis. We demonstrate that nuclear ErbB-2 associates with were identified (Supplemental Figure S2A). We chose to analyze
the interaction between ErbB-2 and the COX-2 promoter ina specific sequence in the COX-2 promoter and upregulates
expression of the COX-2 gene. detail because overexpression of both ErbB-2 and COX-2 has
been implicated in tumorigenesis of many human cancer types
(Howe et al., 2001; Yarden and Sliwkowski, 2001). The clonedResults
DNA fragment, which we named HER-2-associated sequence
(HAS), is located 1750 nucleotides upstream from the transcrip-Nuclear localization of ErbB-2 protein
We detected nuclear ErbB-2 in ErbB-2-expressing human breast tional start site in this gene (Figure 2B). By using primers flanking
the HAS, we detected association of ErbB-2 with the COX-2cancer cell lines using different monoclonal antibodies against
the amino (N) and the carboxyl (C) terminus of ErbB-2. In addition promoter in multiple breast cancer cell lines, including SK-BR-3,
BT474 (Figure 2C), and MCF-7/HER (Figure 2D), as well as into staining of the plasma membrane and perinuclear cytoplasm,
both antibodies clearly showed punctate ErbB-2 expression in the ovarian cancer cell line SK-OV-3 (Figure 2C). In a parallel
ChIP experiment to test the specificity of chromatin associationthe nucleus (the nuclear green spots marked by white arrows
in Figures 1B and 1D–1F). To rule out the possibility that the (Figure 2D), estrogen receptor was recruited to the pS2 pro-
moter, a documented target of estrogen receptor (Berry et al.,nuclear ErbB-2 was contaminated from the endoplasmic reticu-
lum (ER), we stained cells with antibodies against the ER mark- 1989), but not the HAS of COX-2 promoter. Conversely, ErbB-2
did not associate with the pS2 promoter or a distant genomicers calreticulin (Figures 1C, 1E, and 1F) and calnexin (data not
shown). Whereas the perinuclear ErbB-2 mainly colocalized with sequence upstream from the COX-2 promoter. The same ErbB-
2-DNA complex could be detected using ErbB-2 antibodiesER markers, the nuclear ErbB-2 did not (Figures 1B, 1C, 1E,
and 1F). Consistantly, when ErbB-2 expression was stably re- against different epitopes (data not shown). A quantitative ChIP
assay using real-time PCR further validated the recruitment ofconstituted in the MCF-7/HER cells, nuclear immunoreactivity
of ErbB-2 was also detected (see Supplemental Figure S1 at ErbB-2 in the COX-2 promoter (Figure 2E). Significant ErbB-2
recruitment to the COX-2 promoter was detected in MCF-7http://www.cancercell.org/cgi/content/full/6/3/251/DC1). Con-
firming this phenomenon, nuclear expression of ErbB-2 in the stable clones expressing ectopic ErbB-2 but not the MCF-7
parental cells, indicating that COX-2 occupancy was indeedMCF-7/HER cells was also demonstrated by electron micros-
copy (Figure 1G). Using this method, only minimal nuclear ErbB-2 dependent (Figures 2F and 2G). In addition, radiolabeled
HAS oligonucleotide formed a specific complex with nuclearErbB-2 could be detected in the parental MCF-7 cells that ex-
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Figure 1. Nuclear expression of ErbB-2 in BT474 cells
A–C: BT474 cells were stained for nucleus with DAPI (A, blue), ErbB-2 using antibodies recognizing the carboxyl (C) (upper row) or amino (N) terminus (lower
row) (B, green) of ErbB-2, and calreticulin (C, red). See Experimental Procedures for details of the antibodies.
D–F: Image superimpositions are indicated. Authentic ErbB-2 immunoreactive nuclear spots are shown in green (examples indicated by white arrows), and
the perinuclear ErbB-2 colocalized with calreticulin is shown in yellow (E, primarily in the perinuclear region). The staining was visualized by immunofluorescence
microscopy with a deconvolution program.
G: Detection of nuclear ErbB-2 by transmission electron microscopy (TEM). MCF-7/HER cells were processed for immuno-EM, sectioned, and labeled using
monoclonal antibody to the N terminus of ErbB-2 (upper) or mouse IgG (lower) followed by anti-mouse antibody conjugated with 15 nm gold. Scale bar
equals 200 nm. Cy, cytoplasm; Nu, nucleus; NE, nuclear envelope.
H: The nuclear (Nuc) and cytoplasmic (Cyt) fractions of two cell lines (SK-BR-3 and MCF-7/HER cells) were subjected to immunoblot analysis. -tubulin and
poly(ADP-ribose) polymerase (PARP) were used as the cytoplasmic and nuclear markers, respectively.
I: MCF-7/HER cells were treated with the ErbB-2-specific inhibitor AG825 (80 M) for 6 hr. Cytoplasmic (Cyt) and nuclear (Nuc) fractions were then prepared
from the cells, and the expression of ErbB-2, tubulin, and PARP was analyzed by Western blotting.
ErbB-2, which was abolished by cold HAS or anti-ErbB-2 anti- cancers by inducing ErbB-2 internalization and subsequent deg-
bodies but not by the consensus binding sequence of the tran- radation (Klapper et al., 2000). Consistently, our results showed
scription factor AP2 or Sp1, an antibody against CD44, or normal that Herceptin treatment triggered ErbB-2 protein depletion and
mouse IgG (Figure 2H). The ErbB-2 antibodies had no effect on mitigated the association between nuclear ErbB-2 and the
the DNA binding activity of other transcription factors (data not COX-2 promoter (Figure 3A).
shown). These results demonstrate that nuclear ErbB-2 associ- As mentioned above (Figure 1I), the intrinsic tyrosine kinase
ates with a specific genomic DNA sequence in the COX-2 pro- activity of ErbB-2 is critical for its nuclear expression. Consis-
moter and that the ChIP cloning strategy can be used to identify tently, the wild-type ErbB-2 targeted the COX-2 promoter more
target DNA sequences for nuclear receptor tyrosine kinases. efficiently than did the kinase-deficient (kd) mutant, as demon-
strated by stable transfectants established in the MCF-7 cell
line (Figure 3B). Similar results were obtained using transientFunctional ErbB-2 is required for formation
transfection, in which the wild-type ErbB-2 also bound DNAof ErbB-2-COX-2 promoter complex
more efficiently than the kd mutant (Supplemental Figure S3A).It is known that ErbB-2 can be downregulated by Herceptin,
which has been used in clinic to target ErbB-2-overexpressing In addition, treating cells with the ErbB-2-specific tyrosine ki-
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Figure 2. Nuclear ErbB-2 in association with the COX-2 promoter
A: A simplified flow chart of the ChIP-cloning procedure. Nuclei from the fixed ErbB-2-expressing breast cancer cells BT-474 were sonicated to fragment
the genomic DNA. The ErbB-2-DNA complexes were next immunoprecipitated by an anti-ErbB-2 antibody. Copurified DNA fragments were cloned and
the DNA was identified by sequencing. Genomic locations of the identified DNA sequences were determined by querying the GenBank.
B: The sequence in the COX-2 promoter associated with ErbB-2 (boxed sequence). The nucleotide sequence required for ErbB-2 association is in red (see
Figure 4 for details). The PCR primers for ChIP analysis are shown by small arrows with the coordinates indicated.
C: ErbB-2-COX-2 association was confirmed in breast (SK-BR-3, BT474) and ovarian (SK-OV-3) cancer cell lines. ChIP was performed using either monoclonal
anti-ErbB-2 antibody or IgG as the negative control. The target DNA was amplified by PCR using flanking primers as diagrammed in B.
D: The pS2 promoter and the distal upstream region of the COX-2 promoter (Upstream) were examined by ChIP for the occupancy of ErbB-2 and estrogen
receptor (ER) using anti-ErbB-2, anti-ER, or IgG antibody.
E: Quantitative real-time PCR was used to verify the ChIP result obtained by conventional PCR as shown in the inset.
F: Immunoblotting analysis was performed to verify the expression and phosphorylation of ErbB-2 in freshly established MCF-7 cell lines with (ErbB2) or without
(Vector) ectopic ErbB-2 expression.
G: ChIP analysis using anti-ErbB-2 antibody on the same MCF-7 derivatives characterized in F. Either the COX-2 promoter (COX2) or the upstream region
of the COX-2 promoter (Upstream) was tested as described in C and D. The input was also amplified using the upstream primers as a positive control
(Input).
H: The radiolabeled HAS oligonucleotide (the boxed sequence in Figure 2B) was used as the probe for electrophoretic mobility shift assay (EMSA). Lanes
1–4, the labeled probe was incubated with no antibody (lane 1) or with antibodies against ErbB-2 (lane 2), CD44 (lane 3), or IgG (lane 4). Lanes 5–8,
competition assay using the cold oligonucleotides as indicated. Lanes 9–11, the binding reactions containing nuclear extracts and the labeled probe was
challenged by adding different antibodies. The arrow indicates the ErbB-2/oligonucleotide complex. The stars indicate the disappeared ErbB-2-oligonucleo-
tide complex competed by the cold HAS or the ErbB-2 antibodies. Relative intensities (ratio) of the indicated bands were shown at the bottom of the gel.
NE, nuclear lysate.
nase inhibitor AG825, which prevented nuclear translocation of ErbB-2 inhibited its binding to the COX-2 promoter. These re-
sults together indicate that formation of the ErbB-2-COX-2 pro-ErbB-2 (Figure 1I), consistently inhibited the association be-
tween ErbB-2 and the target COX-2 promoter (Supplemental moter complex depends on ErbB-2 expression and requires
tyrosine kinase activity of ErbB-2.Figure S3B). Thus, suppressing the tyrosine kinase activity of
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Figure 3. Formation of the ErbB2-COX2 promoter complex required functional, kinase-competent ErbB-2 protein
A: The MCF-7 stable cell line expressing wild-type ErbB-2 was treated with or without Herceptin (20 g/ml) for 84 hr, then processed for ChIP and Western
blot analysis using ErbB-2 antibody. Tubulin expression is shown as loading control.
B: Left, MCF-7 cell stable clones of wild-type ErbB-2 (wt), the kinase-deficient mutant of ErbB-2 (kd), or the vector (Vec) were tested for the occupancy of
ErbB-2 on the COX-2 promoter by ChIP using ErbB-2 antibody; Right, immunoblot analysis for phosphorylated (ErbB2-P) and the total expression of ErbB-2
(ErbB2) and estrogen receptor (ER), which was used as an internal control.
Transactivation of the COX-2 promoter by ErbB-2 ErbB-2-mediated COX-2 transactivation, COX-2 full-length pro-
moter containing the wild-type or the corresponding mutatedthrough HAS DNA sequence
To further investigate functionality of nuclear ErbB-2, we tested sequence at the HAS was cotransfected with ErbB-2 into MCF-7
cells. Expression of ErbB-2 was able to induce higher reporterwhether ErbB-2 associated with transactivation activity. To this
end, we found that the C-terminal domain (CD) of ErbB-2 con- gene expression from the wild-type than the HAS-mutated full-
length promoter (Figure 5A). Thus, the HAS on the COX-2 pro-tained an intrinsic transactivation activity, as the Gal4-CD fusion
protein induced a dramatic activation function toward a reporter moter plays a significant role in responding to the nuclear ErbB-2
transactivation function. However, the full-length promoter alsogene under the control of a Gal4 binding sequence in the pro-
moter (Figure 4A). To assess the transactivation potential of contains other transcription factor binding elements that can be
modulated through the traditional signal transduction pathways.ErbB-2 in vivo, a 200 bp region containing the HAS was sub-
cloned to control a luciferase reporter system. ErbB-2 cotrans- To avoid the interference from the rest of the promoter se-
quence, the trimeric repeats of either the wild-type HAS orfection with the HAS-luciferase receptor induced the reporter
activity (Figure 4B). We reasoned that, if the HAS mediates the corresponding mutant in the identified core sequence were
subcloned into a plasmid to control a luciferase reporter. Co-ErbB-2-dependent gene activation, abolishing the ErbB-2-HAS
interaction should therefore inhibit the activation. To test this transfection of the ErbB-2-expressing plasmid induced the re-
porter activity driven by the wild-type, but not the mutant, HAShypothesis, we first determined whether the recruitment of
ErbB-2 depends on specific nucleotide residues on the HAS. (Figure 5B). On the other hand, the HAS-mediated reporter activ-
ity responded only to the wild-type ErbB-2 but not to the mutantThe nucleotides of the HAS were mutated in series by transver-
sion-transition (A to C or T to G, for example) in 5-base windows. ErbB-2, which can not translocate to the nucleus (Supplemental
Figure S2C). Thus, these results show that ErbB-2 formed aThe resultant double-strand mutant oligonucleotides were then
used to compete with the wild-type HAS in EMSA assays. The complex with the COX-2 promoter in the nucleus and transacti-
vated the COX-2 gene promoter. Consistently, ectopic expres-mutants lost their competitive activity, which would suggest
that the mutated sequences are critical for ErbB-2 association. sion of ErbB-2 enhanced the mRNA and protein expression
from the endogenous COX-2 gene (Figure 5C). In addition toThus, we identified a subsequence critical for ErbB-2 associa-
tion, with region C being the most important, followed by the COX-2, functional verification of the PRPK promoter, which was
also identified by ChIP cloning (Supplemental Figure S2A), dem-flanking regions B and D (Figure 4C; Table 1). A more detailed
permutation analysis in regions B and D demonstrated that the onstrated that ErbB-2 was able to transactivate the full-length
wild-type promoter, but not the mutant promoter in which theTCAAATTTC sequence (residues marked in red in Figure 2B)
was required for ErbB-2 association. Mutations within this re- ErbB-2-associating DNA motif was mutated, in a kinase activity-
dependent manner (Supplemental Figure S2B). This observationgion of the HAS abolished competivity of the oligonucleotides
(Figure 4D). Further analysis by EMSA showed that the “core” further supports the role of ErbB-2 as a transactivator in the
nucleus.oligonucleotide, which contains the TCAAATTTC sequence
flanked by randomly chosen sequences (Table 1), formed a
specific complex with the nuclear ErbB-2 (Figure 4E). Formation Correlation of COX-2 expression with nuclear
ErbB-2 and ErbB-2-COX-2 promoterof this complex was blocked by competition with the cold HAS,
the core oligonucleotide or anti-ErbB-2 antibodies, but not the complex in human tumor tissues
To explore the physiological function of ErbB-2 in the nuclei ofAP2 binding sequence or the anti-CD44 control antibody. Con-
sistently, biotinylated wild-type, but not the mutant, HAS oligo- human breast tumor cells, a cohort of 30 archived primary breast
cancer tissues were stained by immunohistochemistry for ErbB-2nucleotide was able to associate with ErbB-2 protein in an oligo-
nucleotide pull-down assay (Figure 4F). and COX-2 expression (Figure 6A; Supplemental Figure S4A).
ErbB-2 nuclear expression closely correlated with total ErbB-2To test whether the identified core sequence is critical for
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Figure 4. The ErbB2-COX2 complex was associated with transactivation
A: NIH3T3 cells were cotransfected with 1.8 g of the indicated Gal4 fusion constructs and 0.2 g of the Gal4-luciferase reporter plasmid. The fold induction
of luciferase activity compared with that produced by Gal4 alone was plotted. CD, C-terminal domain (filled box); KD, kinase domain (hatched box).
B: Reporter construct of the 200-bp region (COX200) surrounding the HAS was cotransfected into NIH3T3 cells with an ErbB-2-expressing plasmid (ErbB-2)
or the control vector (pcDNA3). After incubation, cells were collected and luciferase activity was measured.
C: The radiolabeled wild-type HAS probe was incubated in the absence (lane 1) or presence (lanes 2–9) of nuclear lysate, and the resulting ErbB-2-HAS
complex (indicated by an arrow) was challenged with cold HAS (lane 3), mutant oligonucleotides (A)–(D) (lanes 4–7), or control oligonucleotides containing
AP2 (lane 8) or Sp1 (lane 9) binding motif sequence. Relative intensities (ratio) of the indicated bands were shown at the bottom of the gel. NE, nuclear
extract. The sequences of mutant oligonucleotides are listed in Table 1.
D: An EMSA was performed as described in C. Unlabeled wild-type HAS (lane 2) or the indicated mutant oligonucleotides (lanes 3–12) were used to
compete against the radiolabeled ErbB-2-HAS complex (indicated by an arrow). Relative intensities (ratio) of the indicated bands were shown at the
bottom of the gel.
E: The radiolabeled ErbB-2-core complex (lane 2, indicated by an arrow) was challenged with the cold “core” (lane 3), HAS (lane 4), or AP2 (lane 5)
oligonucleotides. Antibodies against ErbB-2 (lanes 6 and 8) or CD44 (lanes 7 and 9) were used to confirm the specific involvement of ErbB-2 in the protein-
DNA complexes. The antibodies were incubated with the binding mixture either at room temperature (lanes 6 and 7) or on ice (lanes 8 and 9), and similar
results were obtained. Relative intensities (ratio) of the indicated bands were shown at the bottom of the gel. NE, nuclear extract.
F: The “core” sequence of the HAS is required for association with ErbB-2 protein. Cellular proteins isolated from MCF-7 and MCF-7/HER cells were precipitated
by biotinylated double-stranded wild-type HAS oligonucleotide or the mutant oligonucleotide in which the core TCAAATTTC motif was mutated. The resulted
protein-DNA complexes were then pulled down by streptavidin-agarose beads, and the ErbB-2 protein associated with the oligonucleotide was eluted
and detected using immunoblot analysis.
expression (p 0.008). While total ErbB-2 expression was asso- other ErbB-2-negative tumor, which was included as a negative
control. These results demonstrate ErbB-2 nuclear expressionciated with COX-2 expression (Pearson correlation coefficient
r  0.399, p  0.029), nuclear expression of ErbB-2 was more and that the COX-2 gene is a target of the nuclear ErbB-2 in
human primary breast tumors. In addition to breast cancer,significantly correlated with COX-2 expression (Pearson correla-
tion coefficient r  0.582, p  0.001). The status of total and nuclear expression of ErbB-2 was also detected in other cancer
types, including small bowel, esophagus, and kidney, sug-nuclear ErbB-2 expression as well as COX-2 expression in the
tumor tissues is summarized in Supplemental Figure S4B. To gesting that nuclear ErbB-2 may be a general phenomenon in
multiple cancer types (Figure 6C). To further address whethertest whether ErbB-2 can be recruited to the COX-2 promoter
in primary tumor tissues, a cohort of fresh surgically excised the enhanced COX-2 expression by ErbB-2 is required for ErbB-
2-mediated malignancy, we compared the effect of COX-2 inhi-tumors from different breast cancer patients were processed
for ChIP analysis. As demonstrated by the representative result bition on the invasion activity between MCF-7 and its ErbB-2
transfectants. As mentioned earlier, the ErbB-2 transfectant ex-shown in Figure 6B, association of ErbB-2 with the COX-2 pro-
moter was detected in a ErbB-2-positive tumor but not in an- pressed higher level of COX-2 than the MCF-7 parental cells
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Table 1. Sequences of the oligonucleotides used in the EMSA experiments
Oligonucleotides Nucleotide sequences Competitivenessa
HAS aactATAAACTTCAAATTTCAGTAgat 
Mutant A aactCGCCCCTTCAAATTTCAGTAgat 
Mutant B aactATAAAAGGACAATTTCAGTAgat 
Mutant C aactATAAACTTCACCGGGCAGTAgat 
Mutant D aactATAAACTTCAAATTTACTGCgat 
Mutant B1 aactATAAAATTCAAATTTCAGTAgat 
Mutant B2 aactATAAAAGTCAAATTTCAGTAgat 
Mutant B3 aactATAAAAGGCAAATTTCAGTAgat 
Mutant B4 aactATAAAAGGAAAATTTCAGTAgat 
Mutant D1 aactATAAACTTCAAATTTCAGTCgat 
Mutant D2 aactATAAACTTCAAATTTCAGGCgat 
Mutant D3 aactATAAACTTCAAATTTCATGCgat 
Mutant D4 aactATAAACTTCAAATTTCCTGCgat 
core gcctgccgagTTCAAATTTCAcccgat 
The corresponding COX-2 promoter sequence complexed with ErbB-2 (as the sequence boxed in Figure 2B) is in capital letters. The mutated nucleotides
are underlined. The identified essential residues for ErbB-2 complex formation are in italics.
aThe compatibility was defined empirically by the EMSA competition assay as shown in Figures 4C–4E, in which the particular cold oligonucleotide was
scored “” if it was able to diminish the ErbB-2-HAS complex. Thus, the mutants B2/B3 and D/D4 defined, respectively, the 5 and 3 boundaries of the HAS
sequence required for ErbB-2-HAS complex formation.
(Figure 5C). Treatment by two classic COX-2-specific inhibitors Discussion
in clinic, celecoxib (Celebrex) and rofecoxib (Vioxx) (Flower,
2003), preferentially suppressed the invasion activity of the Nuclear expression of other human EGFR family proteins,
ErbB-2-expressing cells (Figure 6D). The decreased invasion of namely ErbB-1 (Lin et al., 2001), ErbB-3 (Offterdinger et al.,
the ErbB-2-expressing cells was not due to preferential cell 2002), and ErbB-4 (Ni et al., 2001), was reported recently. The
growth inhibition of the ErbB-2-expressing cells, as the inhibi- identification of the ErbB-2 protein in the nucleus as described
tors had similar effect on both cell lines (Supplemental Figure in this report makes nuclear expression a phenomenon common
S5). Similar results were observed when the breast cancer cell to all EGFR family members. However, the EGFR family proteins
line MDA-MB-435 and its ErbB-2 transfectant were tested (data appear to adopt different mechanisms for nuclear translocation.
not shown). Thus, these results indicate that the ErbB-2-induced Although EGFR and ErbB-3 translocate to the nucleus in full
COX-2 expression is critical for its malignancy. length, ErbB-4 is first processed by membrane proteinases and
the resulting intracellular fragment is then transported to the
nucleus. In the case of ErbB-2, like EGFR and ErbB-3, the
membrane form of the protein seems to be identical to its nuclear
form, as judged by the different antibodies against epitopes at
the amino- and carboxy-terminal regions in immunostaining, as
well as the Western blot analysis that shows that the nuclear
ErbB-2 migrates at the same position as does the total ErbB-2
(Figure 1; Supplemental Figure S1). These results indicate that
ErbB-2 translocates to the nucleus in its full-length form. How-
ever, the possibility that the same receptor may use different
mechanisms for nuclear translocation under different conditions
should not be excluded.
By using an approach combining molecular cloning and
bioinformatic analysis, we demonstrate that the nuclear ErbB-2
targets several gene promoters, including the COX-2 gene pro-
moter, to mediate gene expression. The interaction between
Figure 5. ErbB-2 transactivated the COX-2 promoter through the HAS motif
ErbB-2 and the chromatin provides functional relevance for
A: Full-length COX-2 promoter containing the wild-type (wt) or mutated
ErbB-2 nuclear expression. However, since ErbB-2 lacks any(mut) HAS was cotransfected with ErbB-2 cDNA or the vector control
known structural signatures required for DNA association, it is(pcDNA3) into MCF-7 cells, and the relative luciferase reporter activity was
measured. likely that ErbB-2, and possibly other EGFR family members,
B: A luciferase reporter controlled by the wild-type (wt) or mutant (Mut) does not directly interact with genomic DNA. Rather, they may
HAS as trimeric repeat was cotransfected into MCF-7 cells with an ErbB-2-
associate with other DNA binding nuclear factors. In this regard,expressing plasmid or the vector pcDNA3, and the relative luciferase activity
it has been shown previously that Schwannoma-derived growthwas determined.
C: RNA and protein expression of the COX-2 gene was determined for the factor (SDGF), a rodent ligand for EGFR, can directly bind to
freshly established stable clone of the MCF-7 cells expressing ErbB-2 (HER) AT-rich DNA sequences (Kimura, 1993), which are similar to the
or the vector control (Vec). RT-PCR, reverse transcriptase-polymerase chain
sequences associated with nuclear EGFR (Lin et al., 2001). Inreaction; WB, Western blotting; n.s., nonspecific bands. The same cell lines
were also used in a functional assay as described in Figure 6D. addition, it is worth mentioning that the association of EGFR
CANCER CELL : SEPTEMBER 2004 257
A R T I C L E
Figure 6. ErbB-2 associated with COX-2 expression in primary human breast tumors
A: 30 archived primary breast cancer tissues were analyzed by immunohistochemistry staining using antibodies against ErbB-2 and COX-2 as described in
the Experimental Procedures. In addition to membrane-cytoplasm localization, ErbB-2 expression was also observed in the nucleus in certain areas (examples
indicated by arrows). Statistic analysis confirmed that the nuclear expression of ErbB-2 is significantly correlated with COX-2 expression in the neighboring
tumor tissue sections (see text).
B: ChIP analysis was done for fresh surgically excised tumor samples from breast cancer patients. The DNA-protein complex was pulled down by an anti-
ErbB-2 monoclonal antibody (Ab-5, Oncogene) or IgG, and the resulting DNA was PCR amplified by the primers on the COX-2 promoter as described in
Figure 2. Representative results are shown.
C: Tissue sections derived from different tumor types, including small bowel, breast, esophagus, kidney, and oral tumors were stained with anti-ErbB-2
antibody as described in the Experimental Procedures. White arrows indicate examples of nuclear ErbB-2 expression. Bottom: the oral cancer tissue, although
it expressed high level of ErbB-2 in the cytoplasm, had a lack of nuclear ErbB-2 expression. Another breast cancer tumor tissue was also shown at the
bottom as an ErbB-2-negative example.
D: COX-2 inhibition suppressed invasion activity in ErbB2-expressing breast cancer cells. The enhanced invasion activity of ErbB-2-expressing cancer cells
(HER) was blocked by specific COX-2 inhibitor, celecoxib (50 M) and rofecoxib (100 M), when compared with the parental cells (MCF-7). The invasion
chambers were incubated for 45 hr and the filter was fixed and then stained with DAPI. The number of invaded cells was determined by counting multiple
areas (3) under a fluorescence microscope at 100 amplification power.
with a histone 3 isoform has been reported recently (Blagoev an important issue in cancer chemoprevention and therapy
(Howe et al., 2001; Turini and DuBois, 2002). In breast cancer,et al., 2003). One can therefore envision that the tyrosine kinase
receptors in the nucleus may have a more global genomic func- high level of COX-2 expression has a tight correlation with
ErbB-2 expression (Ristima¨ki et al., 2002; Subbaramaiah et al.,tion. In line with this prospect, nuclear ErbB-2 forms punctate
subnuclear structure, which partially overlaps with the promy- 2002), and the current study described here provides an unex-
pected mechanism in which the nuclear ErbB-2 protein activateselocytic leukaemia (PML) protein (Supplemental Figure S6).
PML, either in the form of matrix-associated discrete nuclear the COX-2 promoter in breast cancer tissues as well as in cul-
tured cancer cells. Besides the tumor types mentioned above,speckles or in the form of soluble nonmatrix distribution, has
been linked to a wide range of nuclear functions including tran- we analyzed a gastric cancer cDNA microarray data set depos-
ited online by others and found that significant correlation be-scriptional regulation (Zhong et al., 2000). Whether and how the
nuclear tyrosine kinase receptors are functionally involved in tween ErbB-2 and COX-2 expression can also be extended to
gastric cancer (Supplemental Figure S7; Chen et al., 2003).chromatic modulating and gene regulation becomes a funda-
mental biological question which should be further explored. Interestingly, the analysis showed that the ErbB-2-COX-2 corre-
lation becomes more significant in metastatic tumor tissues,The cyclooxygenase enzyme COX-2 is one of the major con-
tributors in tumor development. Increased expression of COX-2 suggesting that the interaction between the ErbB-2 and COX-2
pathways is correlated with the advance of tumor developmentoccurs in multiple cells within the tumor microenvironment and
has an impact on angiogenesis, invasiveness, and antiapoptotic in certain cancer types. It remains to be tested whether nuclear
ErbB-2 preferentially occurs in metastatic tumor tissues in gas-potential (Gately, 2000; Takahashi et al., 1999; Tsujii et al., 1997).
Hence, targeting COX-2 activity and expression is becoming tric and other types of cancer. In addition to COX-2, several
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Immunofluorescencedifferent promoter sequences with clustered HAS-like motifs
Cultured cells were fixed with 4% paraformaldehyde for 15 min, permeabil-were identified by searching a promoter database using a HAS-
ized with 0.1% Tween-20 for 15 min, and then immunostained with primaryderived DNA sequence matrix. Among these potential ErbB-2
antibodies (1:200 dilution in PBS with 1% BSA) for 1 hr at 37	C. For ErbB-2,
targets, two genes, namely the Fanconi anemia complementa- the primary antibodies used were Ab-3 (Oncogene; targeting the carboxy-
tion group C (FANCC) gene and the nuclear receptor NR4A3 terminal region) and Ab-5 (Oncogene; targeting the extracellular region).
gene, were verified by ChIP analysis (Supplemental Figure S8A). After three washes with PBS, the FITC-conjugated secondary antibody was
then applied for 45 min at room temperature. The nucleus was stained withErbB-2 expression resulted in transactivation of the FANCC
DAPI (fluorescence) or TOPRO 3 (confocal) before mounting. For immuno-promoter (Supplemental Figure S8B). The FANCC protein is
fluorescence microscopy, the images were captured with a Zeiss AxioPlan2critically involved in the repair of DNA damage generated from
fluorescence microscope with a digital camera. The confocal microscopy
oxidative stress, and expression of FANCC prevents apoptosis was performed by a Zeiss CLM510 laser microscope.
(Ahmad et al., 2002; Pagano and Youssoufian, 2003). Thus,
Chromatin immunoprecipitationwhen combined with appropriate bioinformatic programs and
Cells were fixed with 1% formaldehyde for 10 min, washed, and lysed indatabases, the described ChIP-cloning approach was also able
cell lysis buffer (5 mM HEPES [pH 8.0], 85 mM KCl, 0.5% NP-40) at 4	C forto identify multiple nuclear targets sharing similar binding motifs.
30 min. The nuclei were released by a Dounce homogenizer and then lysedThe function of tyrosine kinase receptors as signaling mole-
in 100–200 l of nuclei lysis buffer (Tris-HCl 50 mM [pH 8.0], EDTA 10 mM,
cules on the cell membrane has been well documented to play SDS 1%). The lysate was sonicated on ice, and the supernatant was diluted
a major role in fundamental cell biology in the last decades. 10-fold with dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA,
16.7 mM Tris-HCl [pH 6.8], 167 mM NaCl). 1 g of antibody was added toDespite the fact that many tyrosine kinase receptors and their
0.5–1 ml of the lysate and rotated at 4	 for overnight. The immunocomplexescognate growth factors were found to be located in the nucleus,
were then pulled down by protein G-conjugated magnetic Dynabeads (Dynalthe functionality of tyrosine kinase receptors in nucleus is virtu-
Biotech). The beads were washed with wash buffer (0.1 M sodium phosphate
ally unknown. This is partly due to the lack of an efficient strategy buffer [pH 6.8], 0.1% Tween-20) for 4 times, and the bound protein was
to identify their nuclear targets. In the current study, we devel- eluted twice with 30 l 0.1 M citrate (pH 3.0). Then, 240 l extraction buffer
oped a cloning strategy involving ChIP to identify specific DNA (0.1% SDS, 50 mM NaHCO3, 5 l of 10 mg/ml RNase, 18 l of 5 M NaCl)
was added to the pooled elutent and incubated at 65	C overnight. Thesequences as nuclear targets for the nuclear ErbB-2 in vivo.
reverted DNA was purified with a miniprep spin column (Qiagen) and thenThe strategy used in the current study is simpler and more
eluted in 50 l of 10 mM Tris-HCl (pH 8.0). The COX-2 promoter region wasphysiologically relevant than the casting method that we pre-
amplified by conventional PCR (with primers CTTCAAAATAAGCTTGAATT
viously used to identify DNA sequences for EGFR nuclear tar- CAGGATTGTAATG and CTTTTTGATAATTTAATAATTTCAATCTTCTGTTTC)
gets (Lin et al., 2001). Thus, it may serve as a general approach or a real-time PCR (with primers CAATAAATAGGAGTGCCATAAATG and
to identify nuclear targets for other tyrosine kinase receptors ACGGATGACTAAAATTCCATCT and the probe 5-FAM-AAGCCTTTCTCC
TCCTCTAGTCAT-BHQ-3). The PCR program was: 95	C for 15 min, followedthat were detected in the nucleus and to facilitate understanding
by 30 to 35 cycles at 95	C for 30 s, 53.5	C for 1 min, and 72	C for 1 min.of the functions of nuclear tyrosine kinase receptors that have
For real-time PCR, the program was 95	C for 3.5 min, followed by 40 cyclesbeen overlooked for decades.
of 95	C for 15 s and 50	C for 30 s. The real-time PCR was performed using
the iCycler system (Bio-Rad).
Experimental procedures
Cloning of the ChIP fragments
Cell culture, antibodies, and tissue slide The immunoprecipitated DNA was processed and cloned as described pre-
All cell lines were maintained in DMEM/F12 with 10% fetal bovine serum. viously (Weinmann et al., 2001). Briefly, the DNA isolated from ChIP was
The following antibodies were purchased: ErbB-2 (Oncogene, San Diego, heated at 68	C for 5 min then cooled to 37	C. One to two units of T4 DNA
CA; DAKO); CD44, calnexin, and PML (Santa Cruz); COX-2 (Oxford Biochem- polymerase was added to the DNA and reaction mix containing the repair
ical); phosphotyrosine (Upstate); PARP (BD Biosciences); and -tubulin buffer (18 mM ammonium sulfate, 66 mM Tris [pH 8.0], 6.6 mM MgCl2, 50
(Sigma). The tissue slide including multiple types of human tumors was mM 
-mercaptoethanol, and 0.5 mM of each nucleotide) and incubated at
purchased from Imgenex. 37	C for 15 min. The reaction was terminated by 1 l of 0.5 M EDTA for a
50 l reaction mix. The processed DNA was cloned into pBluescript vector,
Plasmids and reporter assay which was linearized by Eco321 (Fermentas) and dephosphorylated by calf
The cytoplasmic region (amino acids 727–1234), kinase domain (amino acids intestine phosphatase.
727–986), and C-terminal region (amino acids 987–1234) of ErbB-2 (Yama-
moto et al., 1986) were amplified by PCR and cloned in-frame into the Electrophoretic mobility shift assay
pSG424 vector. The constructs were cotransfected with the pG5-TK-Luc Double-stranded oligonucleotides (Genosys/Sigma-Aldrich) were end la-
reporter plasmid to assess the transactivation activity of the fusion proteins. beled by -32P using T4 polynucleotide kinase (Promega) and then purified
The ErbB-2-associated DNA fragments were cloned into the pGL3-promoter by phenol:chloroform:isoamyl ethanol (25:24:1) extraction. 10 g of nuclear
vector and transfected along with the pRL-TK reporter plasmid (Promega). extracts were incubated with 5 ng radiolabeled probes in 10 mM Tris-HCl
Luciferase assays were carried out using the Dual-Luciferase assay kit (Pro- (pH 7.5), 50 mM NaCl, 1 mM MgCl2, 4% glycerol, 0.5 mM EDTA, 0.5 mM
mega). The pG5-TK-Luc and pSG424 plasmids were generous gifts from DDT, and 1.25 g poly(dI-dC).poly(dI-dC) (Amershan Pharmacia Biotech).
Dr. Marilyn Szentirmay. The wild-type full-length COX-2 promoter-luciferase After 15 min at room temperature, the reaction was terminated by adding 10
construct was provided by Dr. Miguel Angel In˜iguez. gel loading buffer (250 mM Tris-HCl [pH 7.5], 40% glycerol) and separated by
electrophoresis at 4	C in a 5% nondenaturing polyacrylamide gel (acryl-
Cellular fractionation amide:bis-acrylamide, 50:1) containing 0.5 TBE and 2.5% glycerol. In the
The cytoplasmic and nuclear fractions were prepared as described (Maher, competition experiments, nuclear extracts were preincubated with a 200-fold
1996), except that the nuclei were lysed in RIPA buffer (150 mM NaCl, 20 excess of a cold competitive oligonucleotide for 15 min before 32P-labeled
mM Na2 HPO4, 1% TritonX-100, 100 mM NaF, 2 mM Na3VO4, 5 mM PMSF, probes were added. To verify the involvement of ErbB-2 in the complex, 0.5–2.0
2 g/ml aprotinin, 2 g/ml leupeptin, and 0.5 mg/ml benzamidine) by sonica- g of antibodies against ErbB-2 (a cocktail of Ab-3 and Ab-5 from Oncogene
tion (Sonics Vibra Cell, amplitude 20). The fractionation efficiency was as- and Ab-11 from NeoMarker) or equal amount of anti-CD44 antibody (Santa
Cruz) or mouse IgG was added to the mixture containing the nuclear extractssessed by antibodies against -tubulin and PARP.
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and radiolabeled probes and incubated at room temperature or on ice for The cell number on the filter was scored under a fluorescence microscope
with the aid of an image processing software (alphaEaseFC;  Innotech).an additional 10 min.
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